From promises to policies: is big pharma delivering on transparency?BMJ 2014; 348 doi: https://doi.org/10.1136/bmj.g1615 (Published 26 February 2014) Cite this as: BMJ 2014;348:g1615
- Peter Doshi, associate editor
- 1BMJ, London WC1H 9JR, UK
On 30 January, Johnson & Johnson joined a growing cast of major drug companies pledging to grant third party access to their clinical study data.1 Third party access to industry data has occurred on an ad hoc basis for decades. But unprecedented public concern over inaccessible data has led drug companies to streamline the process for granting access.2 3 Since 2012, Boehringer Ingelheim, GlaxoSmithKline, Roche, Sanofi, ViiV Healthcare, and Pfizer have established similar systems to enable access to detailed trial data including clinical study reports and electronic individual participant data. And it would seem we can only expect more announcements in the future, considering the enthusiasm expressed by the Chief Medical Officers Roundtable for a “transparent, harmonized process for access to patient-level clinical trial data.”4 (Box 1)
Box 1. The Chief Medical Officers Roundtable (CMOR) are from 21 companies
Astra Zeneca PLC
Eli Lilly and Company
EMD Serono, Inc
F Hoffman La-Roche
Novartis Pharma AG
Novo Nordisk A/S
Industry’s harmonized approach
Although the details of each company’s approach differ, there seem to be more commonalities than differences in the philosophy and approach of all companies.
Firstly, all companies are in favor of a “controlled access” model of data sharing under which data are not “open access”—that is, free and unrestricted—but rather limited to approved requestors. In the case of Johnson & Johnson, the Yale Open Data Access (YODA) Project team will referee requests for data. For Roche, GlaxoSmithKline, and others using the joint ClinicalStudyDataRequest.com system, the gatekeeper is a four person review panel. (GlaxoSmithKline, which established the panel, has indicated a desire …
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.